Loading...
•
Jun 30, 2025
Alkermes Q2 2025 Earnings Report
Alkermes posted strong Q2 2025 results with growth across proprietary products and continued profitability.
Key Takeaways
Alkermes reported total revenue of $390.7 million and GAAP net income of $87.1 million in Q2 2025, driven by double-digit growth in LYBALVI, ARISTADA, and VIVITROL. The company maintained robust operating margins and reiterated its 2025 financial guidance.
Total proprietary net sales reached $307.2 million, led by LYBALVI, ARISTADA, and VIVITROL.
GAAP net income was $87.1 million with diluted EPS of $0.52.
Adjusted EBITDA totaled $126.5 million, reflecting strong operational efficiency.
Cash, cash equivalents, and investments increased to $1.05 billion.
Revenue by Segment
Forward Guidance
Alkermes reiterated its 2025 financial expectations with confidence in sustained growth across its proprietary portfolio and continued profitability.
Positive Outlook
- Strong proprietary product performance led by LYBALVI and ARISTADA.
- Adjusted EBITDA exceeded $126 million, supporting robust margins.
- Cash position strengthened to over $1.05 billion.
- Positive clinical data from Vibrance-1 boosts narcolepsy program outlook.
- Phase 3 program initiation planned for alixorexton (ALKS 2680).
Challenges Ahead
- Total revenue declined slightly from $399.1M to $390.7M YoY.
- Manufacturing and royalty revenues fell significantly YoY.
- Higher R&D expenses impacted margins.
- SG&A remained flat, showing limited leverage despite revenue pressure.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...